Replies to post #223746 on Biotech Values

[jbog]

RVNC—Thread re possible explanation for weakness in share price:

Revance thought it was prudent selling 6.75 million shares one month ago at $17.00 less commissions, so is the $16.92 price considered weak?

I don't think so.

[dewophile]

I personally am agnostic on the botox biosimilar. A positive meeting with the FDA adds some near term value at the expense of greater competition and price erosion for RT002 down the road. If they scrap the biosimilar I also think it opens the door for an AGN buyout
The only possible near term event that would matter to me is if there is any change to the timeline of filing the NDA